Clinical trial NCT06005532: Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®
Official title: Randomized Double Blind Phase III Trial Comparative Clinical Safety, Efficacy and Immunogenicity of Adalimumab (Manufactured by Mabscale, LLC) to Humira®.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Plaque Psoriasis
Lead sponsor: Mabscale, LLC
Sponsor class: INDUSTRY
First posted: 2023-08-22
Enrollment: 494
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: MABPS-3/2020 is a double-blind randomized multicenter clinical trial comparing efficacy, immunogenicity and safety profiles of Adalimumab (manufactured by Mabscale, LLC) compared to Humira®.

The purpose of the study is to demonstrate efficacy, immunogenicity and safety of Adalimumab (manufactured by Mabscale, LLC) to Humira ® in adult patients with chronic plaque psoriasis of moderate and severe degree.

Detailed description: Adalimumab is a recombinant humanized monoclonal antibody currently being developed by Mabscale LLC, as a proposed biosimilar to Humira®, which is approved as treatment in patients with chronic plaque psoriasis.

This randomized equivalence study is designed to meet the regulatory requirement for approval of a biosimilar product.

Eligibility criteria: Inclusion Criteria:

1. Written informed consent.
2. Male and female patients aged 18-65 years, body weight ≥ 50 kg and ≤ 120 kg.
3. Established clinical diagnosis plaque psoriasis, lasting at least 6 months before the screening.
4. Plaque psoriasis of moderate or severe severity of stable course with:

   * PASI ≥ 12 points;
   * BSA ≥ 10 %;
   * sPGA ≥ 3 points.
5. Patients who have been shown to undergo systemic therapy and/or patients who have had insufficient therapeutic efficacy of at least 1 previous standard systemic therapy for psoriasis, including phototherapy, therapy with cytostatic and immunosuppressive drugs, or who have had intolerance to standard systemic therapy.

Exclusion Criteria:

1. Data on intolerance or hypersensitivity to any components of the drugs, or to any other human proteins, immunoglobulin preparations.
2. A history of severe hypersensitivity reactions of any etiology.
3. Other (other than plaque) forms of psoriasis.
4. Drug-induced psoriasis.
5. Data on the use of the Adalimumab or any preparations of monoclonal antibodies inhibiting TNF-α at any time during life.
6. The presence of Adalimumab antibodies.
7. Extensive surgical intervention performed less than 30 days before the screening period, or planned extensive surgical intervention during the study period.
8. Active or latent tuberculosis
9. Lymphoproliferative diseases, lymphoma, leukemia, myeloproliferative diseases or a history of multiple myeloma.
10. Any other malignant neoplasms currently or in anamnesis within the last 5 years, with the exception of completely removed and/or cured.
11. Confirmed coronavirus infection caused by COVID-19 within 8 weeks prior to the screening period.
12. Anamnestic data on the presence of syphilis, viral hepatitis B, viral hepatitis C, HIV.
13. Vaccination with live or attenuated vaccines within 8 weeks before the screening period.
14. Hepatic and/or renal insufficiency.
15. Pregnancy or lactation.

Primary outcomes:
measure: The proportion of patients who achieved a response according to the PASI criterion of 75 (a decrease in the severity and prevalence of psoriasis by ≥75% from the baseline level assessed by the PASI index)
timeFrame: after 16 weeks of therapy (assessment at Visit 10)
measure: Proportion of patients with positive antibody titer to Adalimumab
timeFrame: 51 weeks of therapy
measure: Percentage of patients who have neutralizing antibodies to Adalimumab
timeFrame: 51 weeks of therapy
Secondary outcomes:
Other outcomes:
Locations:
city: Barnaul
country: Russian Federation
facility: Regional dermatovenerologic dispensary
city: Chelyabinsk
country: Russian Federation
facility: Chelyabinsk Regional Clinical Dermatovenerologic Dispensary
city: Kazan'
country: Russian Federation
facility: Interregional Clinical Diagnostic Center
city: Moscow
country: Russian Federation
facility: City clinical hospital n.a.Botkin
city: Moscow
country: Russian Federation
facility: Rheumatology research Instititue n.a.Nasonova
city: Nizhny Novgorod
country: Russian Federation
facility: State Scientific Center of Dermatovenerology and Cosmetology
city: Novosibirsk
country: Russian Federation
facility: Reafan
city: Pyatigorsk
country: Russian Federation
facility: New Clinic
city: Saint Petersburg
country: Russian Federation
facility: Dermatovenerologic dispensary N10
Study officials:
References: